Skip to main content

Table 2 Association between the MBDA score and achieving sustained DMARD-free remission over time within ACPA-negative RA patients

From: ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation

 ACPA-negative RA patients
Univariable analysesMultivariable analysis
Without MBDA
Multivariable analysis
Including MBDA
HR (95% CI)p valueHR (95% CI)p valueHR (95% CI)p value
MBDA score
 LowReference   Reference 
 Moderate9.40 (1.21–72.85)0.032  6.96 (0.88–55.31)0.067
 High9.73 (1.33–71.10)0.025  8.19 (1.09–61.78)0.041
Age at disease onset, per year1.04 (1.02–1.07)0.0011.03 (1.01–1.06)0.0061.03 (1.00–1.06)0.036
Female1.43 (0.80–2.55)0.23    
Symptom duration > 12 weeks0.96 (0.54–1.70)0.89    
(Sub)acute symptom onset0.93 (0.51–1.69)0.81    
66-SJC, per joint1.04 (0.99–1.08)0.0991.03 (0.99–1.08)0.151.02 (0.98–1.06)0.40
68-TJC, per joint0.99 (0.96–1.02)0.56    
ESR, per mm/h1.01 (1.00–1.02)0.17    
CRP, per µg/mL1.00 (1.00–1.01)0.36    
RF positivity0.57 (0.29–1.09)0.0880.84 (0.42–1.66)0.610.78 (0.39–1.58)0.50
  1. Of the 141 ACPA-negative RA patients, 48 achieved sustained DMARD-free remission. Baseline variables with a p value < 0.10 in univariable analyses were included in a multivariable analysis to assess the independent relation between baseline variables and sustained DMARD-free remission